Genomic and experimental evidence that alternate transcription initiation of the Anaplastic Lymphoma Kinase (ALK) kinase domain does not predict single agent sensitivity to ALK inhibitors.

Authors

Haider Inam

Published

June 17, 2021

Share your thoughts on this paper...

Supporters

Support the authors with ResearchCoin

Preprint Server

Topics

DOI

10.1101/696294

License

CC-BY

Other Formats

PDF

Genomic and experimental evidence that alternate transcription initiation of the Anaplastic Lymphoma Kinase (ALK) kinase domain does not predict single agent sensitivity to ALK inhibitors.

Authors

Haider Inam

Published

June 17, 2021

Share your thoughts on this paper...

Supporters

Support the authors with ResearchCoin

Preprint Server

Topics

DOI

10.1101/696294

License

CC-BY

Other Formats

PDF

Supporters

Support the authors with ResearchCoin

Preprint Server

Topics

DOI

10.1101/696294

License

CC-BY

Other Formats

PDF

Paper

Paper

Paper

Paper

Genomic and experimental evidence that alternate transcription initiation of the Anaplastic Lymphoma Kinase (ALK) kinase domain does not predict single agent sensitivity to ALK inhibitors.

Supporters

Preprint Server

Topics

DOI

License

Other Formats

Genomic and experimental evidence that alternate transcription initiation of the Anaplastic Lymphoma Kinase (ALK) kinase domain does not predict single agent sensitivity to ALK inhibitors.

Supporters

Preprint Server

Topics

DOI

License

Other Formats

Supporters

Preprint Server

Topics

DOI

License

Other Formats